Alcohol and hepatocellular carcinoma: a review and a point of view
- PMID: 25473148
- PMCID: PMC4239482
- DOI: 10.3748/wjg.v20.i43.15943
Alcohol and hepatocellular carcinoma: a review and a point of view
Abstract
It is well recognized that one cause of chronic liver disease and hepatocellular carcinoma (HCC) is alcohol consumption. Research in Italy and the United States concludes that the most common cause of HCC (responsible for 32% to 45% of HCC) is alcohol. It has recently been shown that a significant relationship between alcohol intake, metabolic changes, and hepatitis virus infection does exist. Alcohol may be a factor in the development of HCC via direct (genotoxic) and indirect mechanisms (cirrhosis). There is only one way of diagnosing HCC, which is early identification through surveillance, when curative treatments become possible. After stopping alcohol intake the risk of liver cancer decreases by 6% to 7% a year, and an estimated time period of 23 years is also needed. Therefore, surveillance is also important in former drinkers and, in our opinion, independently from the presence of compensated cirrhosis. In cases of very early stage (VES) and early stage with portal hypertension, liver transplantation is the optimal option; and in cases of associated disease, percutaneous ethanol injections, radiofrequency and microwave ablation are the ideal treatments. Despite the possibility of detecting microvascular invasion with HR, several studies and some randomized controlled trials revealed that overall survival and DSF rates in patients with VES HCC are much the same after ablation and HR. Therefore, ablation can be regarded as a first-line choice for patients with VES HCC. It is important to emphasize that the choice of treatment should be weighed carefully in the context of a multidisciplinary cancer team.
Keywords: Alcohol; Alcoholic liver disease; Hepatocellular carcinoma; Percutaneous ablation.
Figures
Similar articles
-
Management of small hepatocellular carcinoma in cirrhosis: focus on portal hypertension.World J Gastroenterol. 2013 Feb 28;19(8):1193-9. doi: 10.3748/wjg.v19.i8.1193. World J Gastroenterol. 2013. PMID: 23482437 Free PMC article. Review.
-
From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world.World J Gastroenterol. 2017 Aug 7;23(29):5282-5294. doi: 10.3748/wjg.v23.i29.5282. World J Gastroenterol. 2017. PMID: 28839428 Free PMC article. Review.
-
Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system.World J Gastroenterol. 2015 Sep 28;21(36):10327-35. doi: 10.3748/wjg.v21.i36.10327. World J Gastroenterol. 2015. PMID: 26420959 Free PMC article. Review.
-
Repeated percutaneous radiofrequency ablation for hepatocellular carcinoma in patients with cirrhosis: assessment of safety based on liver function and portal hypertension parameters.J Vasc Interv Radiol. 2014 Oct;25(10):1573-9. doi: 10.1016/j.jvir.2014.06.015. Epub 2014 Aug 6. J Vasc Interv Radiol. 2014. PMID: 25108816
-
Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma: a European perspective.Eur J Gastroenterol Hepatol. 2013 Jun;25(6):639-51. doi: 10.1097/MEG.0b013e32835e33bb. Eur J Gastroenterol Hepatol. 2013. PMID: 23628963 Review.
Cited by
-
Inflammatory Response in the Pathogenesis and Treatment of Hepatocellular Carcinoma: A Double-Edged Weapon.Int J Mol Sci. 2024 Jun 29;25(13):7191. doi: 10.3390/ijms25137191. Int J Mol Sci. 2024. PMID: 39000296 Free PMC article. Review.
-
Potential relative quantities of miR-122 and miR-150 to differentiate hepatocellular carcinoma from liver cirrhosis.Noncoding RNA Res. 2022 Feb 6;7(1):34-39. doi: 10.1016/j.ncrna.2022.01.004. eCollection 2022 Mar. Noncoding RNA Res. 2022. PMID: 35224317 Free PMC article.
-
Growth arrest-specific gene 2 suppresses hepatocarcinogenesis by intervention of cell cycle and p53-dependent apoptosis.World J Gastroenterol. 2019 Aug 28;25(32):4715-4726. doi: 10.3748/wjg.v25.i32.4715. World J Gastroenterol. 2019. PMID: 31528096 Free PMC article.
-
Alcohol-related liver disease.Hepatobiliary Surg Nutr. 2024 Apr 3;13(2):347-351. doi: 10.21037/hbsn-24-16. Epub 2024 Mar 27. Hepatobiliary Surg Nutr. 2024. PMID: 38617486 Free PMC article. No abstract available.
-
The Dark Side of the Force: When the Immune System Is the Fuel of Tumor Onset.Int J Mol Sci. 2021 Jan 27;22(3):1224. doi: 10.3390/ijms22031224. Int J Mol Sci. 2021. PMID: 33513730 Free PMC article. Review.
References
-
- Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY, Sterling RK, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, et al. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology. 2011;140:840–849; quiz e12. - PMC - PubMed
-
- Sanyal AJ, Yoon SK, Lencioni R. The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist. 2010;15 Suppl 4:14–22. - PubMed
-
- Sheron N, Hawkey C, Gilmore I. Projections of alcohol deaths--a wake-up call. Lancet. 2011;377:1297–1299. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical